Teesside(n = 268) | Varese(n = 243) | p value | |
---|---|---|---|
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancers (including adenocarcinoma, squamous cell carcinoma, large cell carcinoma and unspecified NSCLC). | |||
*Percentage of all histologically confirmed cases only. | |||
Histologically unconfirmed cases | 75 (28%) | 44 (18%) | <0.01 |
Histologically confirmed cases | 193 (72%) | 199 (82%) | <0.01 |
NSCLC | 147 (55%) | 169 (70%) | <0.001 |
Adenocarcinoma | 42 (22%)* | 60 (30%)* | 0.058 |
Squamous cell carcinoma | 68 (35%)* | 84 (42%)* | 0.156 |
Large cell carcinoma | 21 (11%)* | 4 (2%)* | <0.001 |
Unspecified NSCLC | 16 (8%)* | 21 (11%)* | 0.446 |
SCLC | 46 (24%)* | 30 (15%)* | 0.028 |
NSCLC by clinical stage | |||
Stage I–II | 37 (14%) | 53 (22%) | 0.018 |
Stage III–IV | 104 (39%) | 116 (48%) | 0.042 |
NSCLC not staged due to severe co-morbidity | 6 (2%) | 0 (0%) | 0.019 |